Another mega-analysis found that patients who received immunological drugs targeting one of 7 mechanisms (IL-6, TNF-α, IL-12/23, CD20, COX2, BLγS, p38/MAPK14) had a significant improvement in depression, with the antidepressant effect being higher in the immunotherapy aimed at IL-6, IL-12, and IL-23 [141]. This evidence concerns the gene MAPK14 and depressive symptom measurement.